Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Current Leases (2019 - 2025)

Syndax Pharmaceuticals (SNDX) has 7 years of Current Leases data on record, last reported at $470000.0 in Q4 2025.

  • For Q4 2025, Current Leases changed 0.21% year-over-year to $470000.0; the TTM value through Dec 2025 reached $470000.0, changed 0.21%, while the annual FY2025 figure was $470000.0, 0.21% changed from the prior year.
  • Current Leases reached $470000.0 in Q4 2025 per SNDX's latest filing, up from $329000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $1.0 million in Q1 2024 and bottomed at $299000.0 in Q2 2022.
  • Average Current Leases over 5 years is $571750.0, with a median of $462000.0 recorded in 2023.
  • Peak YoY movement for Current Leases: skyrocketed 220.07% in 2023, then crashed 64.93% in 2025.
  • A 5-year view of Current Leases shows it stood at $361000.0 in 2021, then increased by 20.22% to $434000.0 in 2022, then surged by 138.48% to $1.0 million in 2023, then crashed by 54.49% to $471000.0 in 2024, then fell by 0.21% to $470000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $470000.0 in Q4 2025, $329000.0 in Q3 2025, and $344000.0 in Q2 2025.